Delivery Order 75N98019D00058-75N91023F00002
Award Date
4/24/23
Potential Completion Date
11/30/23
Potential Value
$140K
Federal Agency
National Cancer Institute
Awardee
Societal Cdmo San Diego, LLC
Ultimate Awardee
Recro Pharma, Inc.
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
Q517 - Pharmacy Services
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92121, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for Task Order 19: Z-Endoxifen HCL Capsules, with a ceiling value of $239,627.00. The contract was awarded on February 13, 2017 to Societal CDMO San Diego, LLC, doing business as Irisys Inc., a self-certified small disadvantaged business and limited liability company. The contract is a Delivery Order with a Cost Plus Fixed Fee pricing type, awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH) within the Department...
This federal contract award was issued by the National Cancer Institute, a civilian agency within the Department of Health and Human Services, to Societal CDMO San Diego, LLC (doing business as Irisys Inc.), a self-certified small disadvantaged business and limited liability company. The $196,244.00 cost-plus-fixed-fee delivery order is for the manufacture of the investigational drug INDENOS (LMP744, NSC 706644) for injection in 50 mL fill sizes. Societal CDMO San Diego, a contract development...
This is a federal contract award to Societal Cdmo San Diego, LLC (doing business as Irisys Inc.), a self-certified small disadvantaged business and contract development and manufacturing organization (CDMO). The $82,758 cost-plus-fixed-fee delivery order, awarded by the National Cancer Institute (NCI), is for the production of AZA-TD-CYD capsules for clinical use. The contract has no set-aside designation and is part of the $45 million Drug Formulation and Manufacturing Contracts 2019...
This is a $100,393.00 cost-plus-fixed-fee delivery order awarded by the National Cancer Institute (NCI), a component of the Department of Health and Human Services (HHS), to Societal CDMO San Diego, LLC (dba Irisys Inc.), a self-certified small disadvantaged business and limited liability company. The purpose of this task order is to produce one batch of 10,000 endoxifen capsules, 40 mg per capsule, over the period of performance from January 30, 2020 to June 29, 2020. This contract is not set...
The federal contract award was issued by the National Cancer Institute (NCI), which is part of the U.S. Department of Health and Human Services (HHS), to Societal CDMO San Diego, LLC (doing business as Irisys Inc.), a self-certified small disadvantaged business and limited liability company. The $132,422 cost-plus-fixed-fee contract is for the clinical supply of drug products, including oral and topical dosage forms, to support NCI's research and development efforts, particularly in the areas of...
This is a federal contract award from the National Cancer Institute (NCI), a component of the Department of Health and Human Services (HHS), to Societal CDMO San Diego, LLC, doing business as Irisys Inc. The $79,764 contract is for the clinical supply of an oral and topical drug product under a delivery order contract. The work is related to the NCI's oncology drug development efforts. Societal CDMO San Diego is a small disadvantaged business that provides contract pharmaceutical development,...
This federal contract award was issued by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH) within the U.S. Department of Health and Human Services (HHS), to Societal CDMO San Diego, LLC (doing business as Irisys Inc.), a self-certified small disadvantaged business and contract development and manufacturing organization (CDMO). The $77,283 task order is for the manufacture of 4-thio-2-deoxycytidine capsules, which are likely being developed for use in...
This is a federal contract award from the National Cancer Institute (NCI), a component of the Department of Health and Human Services (HHS), to Societal CDMO San Diego, LLC, doing business as Irisys Inc. The $70,868 task order is for the manufacture of oral and topical dosage forms on a cost-plus-fixed-fee basis. Societal CDMO San Diego, a small disadvantaged business, is a contract development and manufacturing organization (CDMO) that provides pharmaceutical development, manufacturing, and...
This is a federal contract award from the National Cancer Institute (NCI), a component of the Department of Health and Human Services (HHS), to Societal CDMO San Diego, LLC, doing business as Irisys Inc. The $60,424 cost-plus-fixed-fee contract is for the manufacture of a 10 mg strength capsule formulation of the drug 4-thio-2-deoxycytidine under Good Manufacturing Practices (GMP). This contract supports the NCI's efforts in the manufacture of oral and topical dosage forms for investigational...
This is a federal contract award issued by the National Cancer Institute (NCI), a component of the Department of Health and Human Services (HHS), to Societal CDMO San Diego, LLC (doing business as Irisys Inc.), a self-certified small disadvantaged business. The $341,913.00 cost-plus-fixed-fee contract provides for the manufacture, qualification, and stability testing of TARP peptide and TWS-119 formulations to support the NCI's cancer research activities. This contract is issued under the...